FDA Rushes to Grant EUAs to Two More COVID Drugs With No Long-Term Safety or Efficacy Data, While Ignoring a Mountain of Evidence Supporting HCQ, Ivermectin
Let’s start with politics. Under Biden, the FDA has made it very clear for over two years that they do not approve of ivermectin and hydroxychloroquine for treatment of COVID-19, saying there is “insufficient data.” They went so far as to discredit one of these inexpensive treatments on their websites and on social media, implying it’s only for animal deworming (“You are not a horse. You are not a cow. Seriously, y’all. Stop it,” they said).
By contrast, the FDA is silent as the grave when it comes to widespread off-label, long-term drug safety of puberty-blockers and cross-sex hormones being administered to 13-year-old kids that may render them permanently altered and infertile. I don’t expect FDA will tweet “You are not a girl, you are a boy. Seriously, y’all…” anytime soon.
The difference is in narratives. Dangerous off-label usage of drugs is fine to further transgender ideology, but for COVID, it would contradict the narrative that the only way out of the pandemic is through forced, mass vaccination and repeated, titanically ineffective booster shots.
With epidemiological findings in on vaccination and boosters verified from around the world, it only makes sense to consider other available treatment strategies.
And as it turns out, there are readily available drugs that can be used to help lessen COVID symptoms that may prompt unvaccinated people to weigh the risks differently and decline a vaccine or booster shot. According to Anthony Fauci and Joe Biden, this is flatly unacceptable, because, they claim to know better than you and your family about your health and medical history. What if it turns out cheap generic drugs could have been enough for millions of healthy young people forced to mask and vaccinate for the last two years? That would cause Biden a huge political problem, so it’s better if the FDA—an agency with $3.6 billion in discretionary spending and over 18,000 employees—would not publicly confirm the mounting evidence that these generics help with COVID.
No comments:
Post a Comment